The global advanced therapeutics pharmaceutical outsourcing market is expected to surge at a CAGR of 4.4% in the assessment period 2024 to 2034. The market value is projected to increase from US$ 7,592.8 million in 2024 to US$ 11,698.1 million by 2034. The advanced therapeutics pharmaceutical outsourcing market was valued at US$ 7,197.8 million in 2023 and is anticipated to exhibit a y-o-y growth of 4.5% in 2024.
| Attributes | Key Insights |
|---|---|
| Advanced Therapeutics Pharmaceutical Outsourcing Market Size in 2023 | US$ 7,197.8 million |
| Estimated Advanced Therapeutics Pharmaceutical Outsourcing Market Value (2024E) | US$ 7,592.8 million |
| Projected Advanced Therapeutics Pharmaceutical Outsourcing Market Revenue (2034F) | US$ 11,698.1 million |
| Value-based CAGR (2024 to 2034) | 4.4% |
The increasing complexity of advanced therapeutic modalities, such as gene editing, cell therapy, and mRNA-based drugs, requires specialized knowledge and sophisticated manufacturing capabilities. Pharmaceutical companies are turning to outsourcing partners with advanced technical expertise to navigate the complexities of these novel therapies.
The growing pipeline of advanced therapeutic products, driven by breakthroughs in biotechnology and genomics, has led to a surging demand for outsourcing services. As pharmaceutical companies focus on expanding their portfolios with innovative therapies, outsourcing provides a scalable and cost-effective solution for development and production.
The globalization of clinical trials for advanced therapeutics requires a network of partners with a global presence. Outsourcing facilitates access to diverse patient populations, regulatory environments, and manufacturing capabilities worldwide, supporting efficient and accelerated clinical development.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global advanced therapeutics pharmaceutical outsourcing market recorded a historical CAGR of 3.3% from 2019 to 2023. The proliferation of cell and gene therapies represents a transformative shift in healthcare, offering innovative solutions for previously untreatable diseases. The increasing number of companies investing in developing these therapies has created a surge in demand for specialized expertise in manufacturing, quality control, and regulatory compliance.
Cell and gene therapies often involve intricate manufacturing processes, including gene editing, viral vector production, and cell culturing. Outsourcing allows pharmaceutical companies to tap into the specialized capabilities of contract manufacturing organizations (CMOs) with advanced facilities and expertise in these complex processes.
The variability in the production scale for cell and gene therapies, ranging from patient-specific treatments to large-scale manufacturing, necessitates a flexible and scalable approach. Outsourcing allows companies to adjust production volumes based on the specific requirements of their therapies without significant capital investment.
The regulatory landscape for cell and gene therapies is evolving rapidly. Outsourcing partners with a deep understanding of regulatory requirements can guide pharmaceutical companies through the complex approval processes, ensuring compliance and facilitating a smoother path to market.
The increasing adoption of cell and gene therapies is a pivotal driver propelling the growth of the advanced therapeutics pharmaceutical outsourcing market. As pharmaceutical companies prioritize these revolutionary treatment modalities, outsourcing partners equipped with specialized capabilities are becoming indispensable contributors to the successful development and commercialization of advanced therapeutics.
A notable opportunity in the advanced therapeutics pharmaceutical outsourcing market lies in the expanding landscape of mRNA therapies. The increasing focus on mRNA therapies in cancer, infectious diseases, and genetic disorders presents a compelling opportunity for outsourcing partners. As pharmaceutical companies diversify their portfolios, outsourcing providers can offer specialized support in developing and manufacturing mRNA-based treatments.
The versatility of mRNA technology allows for developing a wide range of therapeutic applications. Outsourcing partners can capitalize on this diversity by providing tailored solutions for different mRNA-based treatments, contributing to expanding treatment options available to patients.
mRNA therapies often require specialized expertise in formulation and delivery methods to enhance efficacy and safety. Outsourcing providers focusing on mRNA can offer valuable insights and capabilities in optimizing these critical aspects of therapeutic development.
Principal Consultant
The advanced therapeutics pharmaceutical outsourcing market, while experiencing significant growth opportunities, is also subject to several restrictive factors that pose challenges to its seamless development. When collectively considered, these factors can impact the market dynamics and hinder the full realization of its potential.
The primary restrictive factors is the complex and evolving regulatory landscape governing advanced therapeutics. Regulatory agencies face challenges in establishing clear guidelines as these therapies often involve cutting-edge technologies such as gene editing and cell therapy. This uncertainty can lead to delays in approvals and increase compliance burdens, impacting the speed at which outsourcing services can be leveraged.
The intricate nature of advanced therapeutics, including gene and cell therapies, demands sophisticated scientific expertise and technological capabilities. Finding outsourcing partners with the requisite knowledge in these rapidly advancing fields can be challenging. Technical challenges in scaling up production, maintaining quality, and ensuring consistency also contribute to the complexity.
While outsourcing can offer cost efficiencies, the initial investment in advanced therapeutic technologies and the need for specialized facilities can pose financial challenges. Companies can grapple with the cost of technology transfer, validation, and establishing robust quality control measures with outsourcing partners.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below shows the estimated growth rates of the top five countries. China, Japan, and Spain are set to record high CAGRs of 7.0%, 3.2%, and 2.6%, respectively, through 2034.
| Countries | Value CAGR |
|---|---|
| United States | 1.7% |
| China | 7.0% |
| Japan | 3.2% |
| Germany | 1.6% |
| Spain | 2.6% |
The United States dominated the global market with a 32.6% market share in 2023. The country is expected to exhibit a CAGR of 1.7% throughout the forecast period. The growing demand for personalized medicine and targeted therapies has fueled the development of advanced therapeutics. Outsourcing partners in the United States are well-positioned to support pharmaceutical companies in meeting the demands of a rapidly expanding market for personalized treatments.
The regulatory environment in the United States has increasingly supported advanced therapeutic products. Regulatory bodies, such as the United States Food and Drug Administration (FDA), have implemented expedited pathways and initiatives to facilitate the development and approval of innovative therapies. This regulatory support provides a conducive ecosystem for outsourcing partners to navigate regulatory requirements efficiently.
In 2023, China held a dominant global revenue in East Asia’s market and contributed a share of 7.9% worldwide. The market is expected to grow at a CAGR of 7.0%.
China has witnessed rapid advancements in biotechnology and pharmaceutical research, leading to the development of cutting-edge technologies in gene and cell therapies. The country's commitment to innovation and growing expertise in advanced therapeutics, attract pharmaceutical companies seeking outsourcing partners with specialized capabilities.
China-based outsourcing partners increasingly participate in global clinical trials, allowing sponsors to conduct studies with a more diverse patient population. This globalization trend aligns with the growing emphasis on multi-regional clinical trials, enhancing the attractiveness of China as a destination for outsourcing services.
Germany held 4.4% share in the global market in 2023 and is expected to grow at a CAGR of 1.6% during the forecasted period. Germany has established itself as a leading hub for biopharmaceutical innovation, focusing on advanced therapeutics. The country has a thriving biotechnology sector, research institutions, and a collaborative ecosystem that attracts domestic and international companies seeking outsourcing partners with expertise in cutting-edge therapies.
Germany is investing significantly in biopharmaceutical infrastructure, including state-of-the-art manufacturing facilities and research centers. This infrastructure supports outsourcing partners by providing access to cutting-edge technologies and specialized capabilities required for developing and manufacturing advanced therapeutics.
Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are frequently used by pharmaceutical corporations to outsource different phases of the development process in Japan. Clinical trials, preclinical development, early-stage research, and commercial production are a few examples of these services.
Demand for cutting-edge treatments, such as gene and cell therapies, has increased in Japan. Pharmaceutical companies have been compelled by this demand to look outside for resources and experience to expedite development timeframes and manage the challenges of bringing new medicines to market.
In sophisticated therapies, pharmaceutical companies frequently collaborate strategically with outsourcing partners in Spain. These partnerships seek to maximize resources, take advantage of each other's expertise, and hasten the creation and introduction of novel treatments. Technological developments like automation, analytics, and process optimization help manufacturers of advanced treatments operate more profitably and efficiently in Spain.
The below section shows the commercial manufacturing and packaging segment dominated by phases category. It is forecast to thrive at an 4.0% CAGR between 2024 and 2034. Based on therapy, the gene therapy segment is anticipated to hold a dominant share through 2034. It is set to exhibit a CAGR of 3.8% during the forecast period.
| Segment | Value CAGR |
|---|---|
| Commercial Manufacturing and Packaging (Phases) | 4.0% |
| Gene Therapy (Therapy) | 3.8% |
| Oncology (Indication) | 4.0% |
| Contract Development and Manufacturing Organizations (CDMOs) (Service Type) | 3.7% |
The contract development and manufacturing organizations (CDMOs) held 56.8% market share in 2023. CDMOs offer scalability and flexibility in manufacturing, allowing pharmaceutical companies to adapt production volumes based on the specific requirements of their therapies.
This flexibility is particularly crucial in the dynamic landscape of advanced therapeutics, where production needs may vary widely. CDMOs lead in the advanced therapeutics pharmaceutical outsourcing market due to their specialized expertise, developed infrastructure, flexibility, risk mitigation capabilities, regulatory compliance, cost efficiency, global reach, and collaborative approach to innovation.
The oncology market share in advanced therapeutics pharmaceutical outsourcing was 46.1% in 2023. The oncology pipeline is rich with innovative therapies, including gene therapies, CAR-T cell therapies, and mRNA-based treatments.
The diverse nature of these therapies necessitates specialized expertise and infrastructure, making outsourcing a strategic choice for pharmaceutical companies looking to bring novel oncology treatments to market. This trend will continue as the oncology landscape evolves with ongoing scientific and technological advancements.
Commercial manufacturing and packaging have a considerable presence in the advanced therapeutics pharmaceutical outsourcing market, accounting for 54.9% share in 2023. The commercial manufacturing and packaging services lead the market due to their pivotal role in scaling up production, managing supply chains, and contributing to the overall success of bringing advanced therapeutic products from development to commercialization.
Commercial manufacturing and packaging services are essential for scaling up production from clinical to commercial levels. As advanced therapeutic products progress through clinical trials and receive regulatory approval, the demand for large-scale manufacturing increases, making outsourcing partners with scale-up capabilities indispensable.
Collaborations and acquisitions are the growth strategies that leading companies employ to enhance their capabilities, service offerings, and stay competitive in the dynamic landscape of advanced therapeutics.
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | US$ 7,592.8 million |
| Projected Market Size (2034) | US$ 11,698.1 million |
| Anticipated Growth Rate (2024 to 2034) | 4.4% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia and Pacific; Western Europe; Eastern Europe; Central Asia; Russia and Belarus; Balkan and Baltic Countries; Middle East and Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, Association of Southeast Asian Nations Countries, Australia and New Zealand, GCC Countries, South Africa, Türkiye |
| Key Market Segments Covered | Service Type, Indication, Therapy, Phases, and Region |
| Key Companies Profiled | Croda International Plc; Charles River Laboratories International, Inc.; Catalent, Inc.; QuintilesIMS (IQVIA); Parexel International Corporation; ICON plc; PPD, Inc. (Thermo Fisher Scientific); LabCorp (Laboratory Corporation of America Holdings); Syneos Health; WuXi AppTec; Lonza Group; Piramal Pharma Solutions; SGS SA; Evotec SE; CMC Biologics (Now AGC Biologics); Marken (A UPS Company); Cytovance Biologics; Samsung Biologics; CordenPharma; Recipharm AB; Vetter Pharma International GmbH; Cryoport Systems, Inc.; ProPharma Group; Fujifilm Diosynth Biotechnologies; Medpace; Novotech Pty Ltd.; Axcella Health Inc.; CelerionAshland |
| Report Coverage | Market Forecast, Competition Intelligence, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market was valued at US$ 7,197.8 million in 2023.
The global market is set to reach a valuation of around US$ 11,698.1 million in 2034.
Demand in the global market increased at a 3.3% CAGR from 2019 to 2023.
The global market is estimated to reach US$ 7,592.8 million by 2024.
The United States accounted for around 32.6% share of the global market in 2023.
Germany held around 4.4% share in the global market in 2023.
China accounted for a market value share of around 7.9% in 2023 in the global market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
4. Value Added Insights
4.1. Service Type Adoption, By Region
4.2. Overview of CRO and CDMO Services
4.3. Role of Contract Service Providers
4.4. Regulatory Scenario, By Country
4.5. Industry Deals
4.6. PESTEL Analysis by Region
4.7. PORTER Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Research and Development Funding Outlook
5.1.3. Global Life Expectancy Outlook
5.1.4. Global Oncology Spending Outlook
5.1.5. Growing Geriatric Population
5.2. Forecast Factors - Relevance and Impact
5.2.1. Increase in Research and Development Funding and Grants
5.2.2. Increasing Incidence of Genetic Disorders
5.2.3. Service Type Pipeline
5.2.4. Service Type Innovation Trends
5.2.5. Market Consolidation Activities
5.2.6. Prevalence of Chronic Diseases
5.2.7. Shift Towards Technologically Advanced Service Types
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034
6.1. Historical Market Value (US$ million) Analysis, 2019 to 2023
6.2. Current and Future Market Value (US$ million) Projections, 2024 to 2034
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Service Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ million) By Service Type, 2019 to 2023
7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Service Type, 2024 to 2034
7.3.1. Contract Research Organizations (CROs)
7.3.2. Contract Development and Manufacturing Organizations (CDMOs)
7.4. Market Attractiveness Analysis By Service Type
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ million) Analysis By Indication, 2019 to 2023
8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Indication, 2024 to 2034
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Cardiology
8.3.4. Infectious Diseases
8.3.5. Others
8.4. Market Attractiveness Analysis By Indication
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ million) By Therapy, 2019 to 2023
9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Therapy, 2024 to 2034
9.3.1. Cell Therapy
9.3.2. Gene Therapy
9.3.3. RNA-based Therapies
9.3.4. Others
9.4. Market Attractiveness Analysis By Therapy
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Phases
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ million) By Phases, 2019 to 2023
10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Phases, 2024 to 2034
10.3.1. Preclinical Services
10.3.2. Clinical Services
10.3.3. Commercial Manufacturing and Packaging
10.4. Market Attractiveness Analysis By Phases
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ million) Analysis By Region, 2019 to 2023
11.3. Current and Future Market Size (US$ million) Analysis and Forecast By Region, 2024 to 2034
11.3.1. North America
11.3.2. Latin America
11.3.3. East Asia
11.3.4. South Asia and Pacific
11.3.5. Western Europe
11.3.6. Eastern Europe
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
12.1. Introduction
12.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
12.3.1. By Country
12.3.1.1. United States
12.3.1.2. Canada
12.3.1.3. Mexico
12.3.2. By Service Type
12.3.3. By Indication
12.3.4. By Therapy
12.3.5. By Phases
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Service Type
12.4.3. By Indication
12.4.4. By Therapy
12.4.5. By Phases
12.5. Country Level Analysis and Forecast
12.5.1. United States Market Analysis
12.5.1.1. Introduction
12.5.1.2. Market Analysis and Forecast by Market Taxonomy
12.5.1.2.1. By Service Type
12.5.1.2.2. By Indication
12.5.1.2.3. By Therapy
12.5.1.2.4. By Phases
12.5.2. Canada Market Analysis
12.5.2.1. Introduction
12.5.2.2. Market Analysis and Forecast by Market Taxonomy
12.5.2.2.1. By Service Type
12.5.2.2.2. By Indication
12.5.2.2.3. By Therapy
12.5.2.2.4. By Phases
12.5.3. Mexico Market Analysis
12.5.3.1. Introduction
12.5.3.2. Market Analysis and Forecast by Market Taxonomy
12.5.3.2.1. By Service Type
12.5.3.2.2. By Indication
12.5.3.2.3. By Therapy
12.5.3.2.4. By Phases
13. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
13.1. Introduction
13.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Chile
13.3.1.3. Rest of Latin America
13.3.2. By Service Type
13.3.3. By Indication
13.3.4. By Therapy
13.3.5. By Phases
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Service Type
13.4.3. By Indication
13.4.4. By Therapy
13.4.5. By Phases
13.5. Market Trends
13.6. PESTEL Analysis
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
13.9. Country Level Analysis and Forecast
13.9.1. Brazil Market Analysis
13.9.1.1. Introduction
13.9.1.2. Market Analysis and Forecast by Market Taxonomy
13.9.1.2.1. By Service Type
13.9.1.2.2. By Indication
13.9.1.2.3. By Indication
13.9.1.2.4. By Phases
13.9.2. Chile Market Analysis
13.9.2.1. Introduction
13.9.2.2. Market Analysis and Forecast by Market Taxonomy
13.9.2.2.1. By Service Type
13.9.2.2.2. By Indication
13.9.2.2.3. By Indication
13.9.2.2.4. By Phases
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
14.1. Introduction
14.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Service Type
14.3.3. By Indication
14.3.4. By Indication
14.3.5. By Phases
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Service Type
14.4.3. By Indication
14.4.4. By Therapy
14.4.5. By Phases
14.5. Country Level Analysis and Forecast
14.5.1. China Market Analysis
14.5.1.1. Introduction
14.5.1.2. Market Analysis and Forecast by Market Taxonomy
14.5.1.2.1. By Service Type
14.5.1.2.2. By Indication
14.5.1.2.3. By Therapy
14.5.1.2.4. By Phases
14.5.2. Japan Market Analysis
14.5.2.1. Introduction
14.5.2.2. Market Analysis and Forecast by Market Taxonomy
14.5.2.2.1. By Service Type
14.5.2.2.2. By Indication
14.5.2.2.3. By Therapy
14.5.2.2.4. By Phases
14.5.3. South Korea Market Analysis
14.5.3.1. Introduction
14.5.3.2. Market Analysis and Forecast by Market Taxonomy
14.5.3.2.1. By Service Type
14.5.3.2.2. By Indication
14.5.3.2.3. By Therapy
14.5.3.2.4. By Phases
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034
15.1. Introduction
15.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Association of Southeast Asian Nations Countries
15.3.1.3. Australia and New Zealand
15.3.1.4. Rest of South Asia and Pacific
15.3.2. By Service Type
15.3.3. By Indication
15.3.4. By Therapy
15.3.5. By Phases
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Service Type
15.4.3. By Indication
15.4.4. By Therapy
15.4.5. By Phases
15.5. Country Level Analysis and Forecast
15.5.1. India Market Analysis
15.5.1.1. Introduction
15.5.1.2. Market Analysis and Forecast by Market Taxonomy
15.5.1.2.1. By Service Type
15.5.1.2.2. By Indication
15.5.1.2.3. By Therapy
15.5.1.2.4. By Phases
15.5.2. Association of Southeast Asian Nations Countries Market Analysis
15.5.2.1. Introduction
15.5.2.2. Market Analysis and Forecast by Market Taxonomy
15.5.2.2.1. By Service Type
15.5.2.2.2. By Indication
15.5.2.2.3. By Therapy
15.5.2.2.4. By Phases
15.5.3. Australia and New Zealand Market Analysis
15.5.3.1. Introduction
15.5.3.2. Market Analysis and Forecast by Market Taxonomy
15.5.3.2.1. By Service Type
15.5.3.2.2. By Indication
15.5.3.2.3. By Therapy
15.5.3.2.4. By Phases
16. Western Europe Market 2019 to 2023 and Forecast 2024 to 2034
16.1. Introduction
16.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. United States
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Rest of Western Europe
16.3.2. By Service Type
16.3.3. By Indication
16.3.4. By Therapy
16.3.5. By Phases
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Service Type
16.4.3. By Indication
16.4.4. By Therapy
16.4.5. By Phases
16.5. Country Level Analysis and Forecast
16.5.1. Germany Market Analysis
16.5.1.1. Introduction
16.5.1.2. Market Analysis and Forecast by Market Taxonomy
16.5.1.2.1. By Service Type
16.5.1.2.2. By Indication
16.5.1.2.3. By Therapy
16.5.1.2.4. By Phases
16.5.2. France Market Analysis
16.5.2.1. Introduction
16.5.2.2. Market Analysis and Forecast by Market Taxonomy
16.5.2.2.1. By Service Type
16.5.2.2.2. By Indication
16.5.2.2.3. By Therapy
16.5.2.2.4. By Phases
16.5.3. Spain Market Analysis
16.5.3.1. Introduction
16.5.3.2. Market Analysis and Forecast by Market Taxonomy
16.5.3.2.1. By Service Type
16.5.3.2.2. By Indication
16.5.3.2.3. By Therapy
16.5.3.2.4. By Phases
16.5.4. Italy Market Analysis
16.5.4.1. Introduction
16.5.4.2. Market Analysis and Forecast by Market Taxonomy
16.5.4.2.1. By Service Type
16.5.4.2.2. By Indication
16.5.4.2.3. By Therapy
16.5.4.2.4. By Phases
16.5.5. BENELUX Market Analysis
16.5.5.1. Introduction
16.5.5.2. Market Analysis and Forecast by Market Taxonomy
16.5.5.2.1. By Service Type
16.5.5.2.2. By Indication
16.5.5.2.3. By Therapy
16.5.5.2.4. By Phases
16.5.6. United Kingdom Market Analysis
16.5.6.1. Introduction
16.5.6.2. Market Analysis and Forecast by Market Taxonomy
16.5.6.2.1. By Service Type
16.5.6.2.2. By Indication
16.5.6.2.3. By Therapy
16.5.6.2.4. By Phases
17. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
17.1. Introduction
17.2. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
17.3.1. By Country
17.3.1.1. Russia
17.3.1.2. Hungary
17.3.1.3. Poland
17.3.1.4. Rest of Eastern Europe
17.3.2. By Service Type
17.3.3. By Indication
17.3.4. By Therapy
17.3.5. By Phases
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Service Type
17.4.3. By Indication
17.4.4. By Therapy
17.4.5. By Indication
17.4.6. By Phases
17.5. Country Level Analysis and Forecast
17.5.1. Russia Market Analysis
17.5.1.1. Introduction
17.5.1.2. Market Analysis and Forecast by Market Taxonomy
17.5.1.2.1. By Service Type
17.5.1.2.2. By Indication
17.5.1.2.3. By Therapy
17.5.1.2.4. By Phases
17.5.2. Hungary Market Analysis
17.5.2.1. Introduction
17.5.2.2. Market Analysis and Forecast by Market Taxonomy
17.5.2.2.1. By Service Type
17.5.2.2.2. By Indication
17.5.2.2.3. By Therapy
17.5.2.2.4. By Phases
17.5.3. Poland Market Analysis
17.5.3.1. Introduction
17.5.3.2. Market Analysis and Forecast by Market Taxonomy
17.5.3.2.1. By Service Type
17.5.3.2.2. By Indication
17.5.3.2.3. By Therapy
17.5.3.2.4. By Phases
18. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034
18.1. Introduction
18.2. Key Players Analyzed
18.3. Historical Market Size (US$ million) Analysis by Market Taxonomy, 2019 to 2023
18.4. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034
18.4.1. By Country
18.4.1.1. Saudi Arabia
18.4.1.2. Türkiye
18.4.1.3. South Africa
18.4.1.4. North Africa
18.4.1.5. Rest of Middle East and Africa
18.4.2. By Service Type
18.4.3. By Indication
18.4.4. By Therapy
18.4.5. By Phases
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Service Type
18.5.3. By Indication
18.5.4. By Therapy
18.5.5. By Indication
18.5.6. By Phases
18.6. Country Level Analysis and Forecast
18.6.1. Saudi Arabia Market Analysis
18.6.1.1. Introduction
18.6.1.2. Market Analysis and Forecast by Market Taxonomy
18.6.1.2.1. By Service Type
18.6.1.2.2. By Indication
18.6.1.2.3. By Therapy
18.6.1.2.4. By Phases
18.6.2. Türkiye Market Analysis
18.6.2.1. Introduction
18.6.2.2. Market Analysis and Forecast by Market Taxonomy
18.6.2.2.1. By Service Type
18.6.2.2.2. By Indication
18.6.2.2.3. By Therapy
18.6.2.2.4. By Phases
18.6.3. South Africa Market Analysis
18.6.3.1. Introduction
18.6.3.2. Market Analysis and Forecast by Market Taxonomy
18.6.3.2.1. By Service Type
18.6.3.2.2. By Indication
18.6.3.2.3. By Therapy
18.6.3.2.4. By Phases
18.6.4. North Africa Market Analysis
18.6.4.1. Introduction
18.6.4.2. Market Analysis and Forecast by Market Taxonomy
18.6.4.2.1. By Service Type
18.6.4.2.2. By Indication
18.6.4.2.3. By Therapy
18.6.4.2.4. By Phases
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Companies
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Benchmarking
20.2. Competition Dashboard
20.3. Key Development Analysis
20.4. Key Promotional Strategies, By Manufacturers
20.5. Competition Deep Dive
20.5.1. Charles River Laboratories International, Inc.
20.5.1.1. Overview
20.5.1.2. Service Portfolio
20.5.1.3. Sales Footprint
20.5.1.4. Key Financials
20.5.1.5. Key Developments
20.5.1.6. Strategy Overview
20.5.1.7. SWOT Analysis
20.5.2. Catalent, Inc.
20.5.3. QuintilesIMS (IQVIA)
20.5.4. Parexel International Corporation
20.5.5. ICON plc
20.5.6. PPD, Inc. (Thermo Fisher Scientific)
20.5.7. LabCorp (Laboratory Corporation of America Holdings)
20.5.8. Syneos Health
20.5.9. WuXi AppTec
20.5.10. Lonza Group
20.5.11. Piramal Pharma Solutions
20.5.12. SGS SA
20.5.13. Evotec SE
20.5.14. CMC Biologics (Now AGC Biologics)
20.5.15. Marken (A UPS Company)
20.5.16. Cytovance Biologics
20.5.17. Samsung Biologics
20.5.18. CordenPharma
20.5.19. Recipharm AB
20.5.20. Vetter Pharma International GmbH
20.5.21. Cryoport Systems, Inc.
20.5.22. ProPharma Group
20.5.23. Fujifilm Diosynth Biotechnologies
20.5.24. Medpace
20.5.25. Novotech Pty Ltd.
20.5.26. Axcella Health Inc.
20.5.27. Celerion
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Advanced Therapeutics Pharmaceutical Outsourcing Market
